Beyond Amyloid: Building the Next Alzheimer’s Disease Therapeutic Ecosystem

Key Takeaways

• FDA-approved amyloid-directed antibodies have opened a new era in Alzheimer’s disease therapy, but they do not address the full biological complexity of the disease.

• Emerging Alzheimer’s therapeutic targets include tau pathology, microglial and neuroinflammatory signaling, synaptic dysfunction, mitochondrial impairment, mitophagy, vascular pathology, and blood–brain barrier dysfunction.

• Tau-directed strategies include immunotherapies, antisense oligonucleotides, aggregation inhibitors, microtubule stabilizers, and approaches designed to enhance pathological tau clearance.

• Neuroinflammation, microglial biology, and TREM2-targeted approaches illustrate both the promise and complexity of immune modulation in Alzheimer’s disease.

• Future Alzheimer’s drug development may increasingly depend on biomarker-driven patient selection, target engagement, disease-stage specificity, and rational combination therapies.

For decades, Alzheimer’s disease research has been shaped by the amyloid hypothesis, and the recent arrival of amyloid beta-directed antibodies has changed the therapeutic conversation in a way that previous investigational approaches could not. Leqembi / lecanemab received traditional approval from the U.S. Food and Drug Administration (FDA), which identified it as an amyloid beta-directed antibody for Alzheimer’s disease.¹ Kisunla/donanemab was subsequently approved by the FDA for adults with Alzheimer’s disease, with treatment initiated in patients with mild cognitive impairment (MCI) or mild dementia stage disease, the population studied in clinical trials.² Those approvals established a new clinical and regulatory context for disease-modifying therapy in Alzheimer’s disease.

That progress, however, has also sharpened the need for a broader therapeutic strategy. Alzheimer’s disease remains a major public health challenge, with an estimated 7.4 million Americans aged 65 and older living with the disease in 2026.³ The existence of approved amyloid-directed antibodies does not resolve the full biological complexity of Alzheimer’s disease, nor does it eliminate the need for therapies that address other contributors to cognitive decline, disease progression, and patient heterogeneity.

The next phase of Alzheimer’s drug development is therefore likely to be shaped less by a single target and more by a wider map of disease biology. Tau pathology, neuroinflammation, microglial signaling, synaptic dysfunction, mitochondrial impairment, vascular contributions, blood–brain barrier (BBB) biology, and mixed pathology all offer distinct ways of understanding and potentially modifying the disease. Combination therapy has also become a serious development concept, based on the recognition that Alzheimer’s disease is complex and multifaceted, and that future strategies may need to address amyloid, tau, inflammation, vascular injury, synaptic plasticity, and co-pathologies together or in sequence.⁴

This broader view should not be treated as a rejection of amyloid-directed therapy. In contrast, the anti-amyloid era opens the door to more sophisticated therapeutic development. Once disease modification becomes possible in one pathway, the field can begin asking harder questions about which additional mechanisms matter, how they interact, which patients are most likely to benefit from a given intervention, and how biomarkers can guide treatment across disease stages.

Tau remains one of the most prominent non-amyloid therapeutic target areas in Alzheimer’s disease. While amyloid beta has dominated much of the field’s history, tau provides a complementary axis for disease modification because it represents another major pathological feature of Alzheimer’s disease and has become the focus of multiple therapeutic strategies.5 This makes tau one of the clearest starting points for expanding Alzheimer’s drug development beyond amyloid.

The tau-directed landscape is also broader than any single modality. Current tau-targeting strategies include immunotherapies, antisense oligonucleotides (ASOs), aggregation inhibitors, microtubule stabilizers, and approaches intended to enhance pathological tau clearance.⁵ Immunotherapies account for most tau-targeting agents in clinical trials, but the range of approaches reflects the difficulty of translating tau biology into therapy and the need to intervene at different points in tau production, aggregation, spread, or clearance.⁵

ASO-based therapy provides one of the more concrete examples of a non-antibody approach to tau. MAPTRx / BIIB080, a tau-targeting ASO, was evaluated in a phase Ib study in mild Alzheimer’s disease and showed target engagement, with dose-dependent reductions in cerebrospinal-fluid (CSF) total tau.⁶ That finding supports the feasibility of lowering tau biology through a targeted molecular approach, although larger controlled trials are still needed to determine whether the observed biomarker effects translate into clinical efficacy.

Tau therefore illustrates both the opportunity and the difficulty of Alzheimer’s disease modification. The target is biologically compelling, multiple modalities are being explored, and early target-engagement data exist for at least one ASO strategy. At the same time, the field still needs to determine how tau-directed interventions should be timed, which patients are most appropriate, which biomarkers best capture target engagement and downstream effect, and whether tau therapies will be most effective alone or as part of combination regimens.

For drug developers, tau also highlights the difference between showing that a target can be modulated and proving that target modulation changes disease trajectory. CSF tau reduction, antibody engagement, or effects on tau-related biomarkers can support biological activity, but Alzheimer’s disease trials ultimately need to demonstrate meaningful effects on disease progression, cognition, or function. As the field moves beyond amyloid, tau may become not only a therapeutic target but also a test case for how Alzheimer’s programs translate mechanistic precision into clinical benefit.

Neuroinflammation and microglial biology have become important target areas in Alzheimer’s disease research. Inflammatory dysregulation, microglial activity, neuroinflammation-associated biomarkers, and anti-inflammatory strategies are all part of the current therapeutic discussion.⁷ Neuroinflammation-targeting drugs are already being evaluated clinically in Alzheimer’s disease, reflecting a shift from viewing inflammation mainly as a consequence of neurodegeneration to treating immune biology as a modifiable part of the disease process.¹⁰

Microglia are central to this discussion because they are the brain’s resident immune cells and participate in inflammatory responses relevant to Alzheimer’s disease biology.⁷ The therapeutic question is not simply whether microglia should be activated or suppressed. The more difficult challenge is determining how microglial states influence disease pathology at different stages and how an intervention can promote protective functions without worsening harmful inflammatory activity.

TREM2 has become one of the most visible examples of this complexity. TREM2 is a microglial/myeloid receptor implicated in Alzheimer’s disease genetics and is being targeted by multiple pharmacotherapies.⁸ AL002, an investigational TREM2 agonistic antibody, has been evaluated preclinically and in a first-in-human study for Alzheimer’s disease.⁹ These programs show that immune modulation is not simply a theoretical extension of Alzheimer’s biology but an active area of therapeutic development.

The TREM2 example also underscores why immune-directed therapy in Alzheimer’s disease requires caution. TREM2 biology is not a straightforward “turn microglia on” strategy, because its effects on amyloid and tau biology may differ, and its role may vary with disease context.⁸ A receptor that appears protective or beneficial in one pathological setting may have different consequences in another, particularly when amyloid, tau, inflammation, and neurodegeneration are all present.

Other neuroinflammation-directed approaches broaden the field beyond TREM2. Investigational drugs targeting neuroinflammation in Alzheimer’s disease include p38 mitogen-activated protein kinase (MAPK) inhibitors such as neflamapimod and MW150.¹⁰ Their inclusion in the clinical landscape reflects interest in modulating inflammatory signaling pathways that may contribute to disease progression.10 These examples should be presented carefully, as evidence of development activity rather than proof that any given neuroinflammatory strategy has established efficacy.

Immune modulation may ultimately require some of the most nuanced development strategies in Alzheimer’s disease. Biomarkers will be needed to identify whether a target is engaged and whether the immune response is shifting in a desirable direction. Disease stage may matter, because the role of microglia and inflammation may change as pathology evolves. Patient selection may also be critical, particularly if genetic or biomarker-defined subgroups respond differently to immune-directed interventions. In that sense, neuroinflammation offers a compelling therapeutic frontier, but one that is unlikely to reward simplistic approaches.

A broader Alzheimer’s therapeutic strategy must also address the biology most closely tied to cognition. Alzheimer’s disease can be framed as a synaptopathy, with synaptic dysfunction and synapse loss relevant to cognitive decline.¹¹ This shifts attention from pathological deposits alone to the functional connections that allow neurons to communicate and support memory, learning, and other cognitive processes.

Synaptic dysfunction is important because cognitive decline is what patients and families experience most directly. Amyloid plaques, tau pathology, inflammation, and mitochondrial dysfunction may all contribute to disease biology, but the progressive loss of cognitive function reflects damage to neural circuits and synaptic communication. Synaptic biology therefore provides a rationale for therapies focused on cognitive preservation, not only the reduction of plaques, tangles, or other pathological markers.¹¹

The timing of synaptic injury also matters. Loss of neuronal synapses occurs early in Alzheimer’s disease pathogenesis and is associated with cognitive decline.¹² That makes synaptic dysfunction more than a late-stage marker of neuronal damage. It can be understood as an early and clinically meaningful feature of disease progression that may help explain why cognitive symptoms emerge and worsen as Alzheimer’s disease advances.

For therapeutic development, synaptic biology raises a different set of questions than protein-targeted approaches. A treatment designed to preserve synapses or support synaptic function may not produce the same biomarker profile as an amyloid- or tau-lowering therapy. Developers may need to think carefully about how to measure target engagement, how to demonstrate functional effects, and how to connect synaptic preservation with meaningful clinical outcomes. Cognitive endpoints, digital measures, electrophysiological readouts, imaging approaches, or fluid biomarkers may all become relevant depending on the mechanism, although specific tools should be selected based on validated evidence for each program.

The synaptopathy framework also helps explain why disease modification should not be defined too narrowly. If an intervention slows the deterioration of synaptic function or preserves cognitive circuitry, it may contribute to disease modification even if it does not directly clear amyloid or tau. Conversely, upstream effects on amyloid or tau may need to be evaluated in part by whether they preserve downstream synaptic integrity and function.

This section of the Alzheimer’s pipeline remains less concrete than amyloid- or tau-directed therapy, and specific synaptic targets should not be overrepresented without further support. Still, synaptic dysfunction is essential to therapeutic approaches beyond amyloid because it links molecular pathology to the clinical reality of cognitive decline. For a field seeking treatments that matter to patients, preserving synaptic function may be as important as modifying the markers that define disease biology.

Mitochondrial biology adds another dimension to the expanding Alzheimer’s therapeutic landscape. Mitochondrial dysfunction is an early and prominent feature of Alzheimer’s disease and has been described as a potential therapeutic target.¹³ This places mitochondria within the disease-modification conversation, not simply as downstream casualties of neurodegeneration but as contributors to cellular vulnerability and impaired neuronal resilience.

Mitochondria are central to cellular energy production and homeostasis, and neurons are especially dependent on mitochondrial function because of their high energetic demands. Within the literature, mitochondrial dysfunction is linked to Alzheimer’s disease pathogenesis and is being explored as a targetable feature of disease biology.¹³ Therapeutic strategies targeting mitochondrial dysfunction include pharmacological interventions and gene therapy,.¹⁴

Mitophagy provides a more specific mitochondrial target area. Mitophagy is the process by which damaged or dysfunctional mitochondria are cleared, and impaired mitophagy is relevant to Alzheimer’s disease biology.¹⁵ Therapeutic strategies aimed at stimulating mitophagy are being discussed in Alzheimer’s disease research, reflecting interest in restoring mitochondrial quality control as a way to support neuronal health.

Amyloid- and tau-directed strategies focus largely on hallmark protein pathologies, while mitochondrial and mitophagy-directed approaches focus on cellular resilience. The aim is not necessarily to remove a single toxic species but to improve the ability of neurons and other brain cells to maintain function under pathological stress. That distinction matters because Alzheimer’s disease progression likely reflects not only the accumulation of pathology but also the declining ability of cells to cope with metabolic, proteostatic, inflammatory, and vascular stressors.

Mitochondrial approaches also raise difficult translational questions. A therapy may affect mitochondrial function, mitophagy, or cellular energetics, but developers still need to connect those effects to disease-stage biology, measurable biomarkers, and clinical outcomes. Because mitochondrial dysfunction can be broad and multifactorial, target specificity may be a challenge. Programs will need to define whether they are addressing mitochondrial biogenesis, quality control, oxidative stress, energy metabolism, mitophagy, or another mitochondrial process and then select biomarkers that match that mechanism.

For Alzheimer’s drug development, the value of mitochondrial biology may lie in its ability to connect multiple disease features. Protein aggregation, inflammation, synaptic failure, and vascular dysfunction can all place stress on neuronal systems. Mitochondrial impairment may reflect and amplify that stress, while mitophagy may represent one way to restore cellular quality control. The therapeutic opportunity is promising, but the field will need rigorous mechanistic and clinical validation to determine where mitochondrial interventions fit within the broader treatment ecosystem.

A full “beyond amyloid” strategy also needs to move beyond neuron-centered biology. Vascular contributions are linked to cognitive impairment and dementia, including Alzheimer’s disease.¹⁶ In older adults, vascular pathology, vascular brain injury, neurovascular-unit alterations, BBB abnormalities, and mixed pathologies are relevant to Alzheimer’s disease and dementia.¹⁷ These findings support a systems-level view in which Alzheimer’s disease is influenced not only by plaques, tangles, neurons, and glia but also by the vascular and barrier systems that support brain health.

The vascular contribution is especially important because many patients do not present with a single isolated pathology. Mixed pathology complicates diagnosis, prognosis, and therapeutic development. A patient may have Alzheimer’s pathology alongside vascular brain injury or other co-pathologies, which can influence cognitive decline and potentially affect response to therapy.¹⁷ This complexity reinforces the need for patient stratification and biomarker-informed development, particularly as disease-modifying therapies become more widely available.

BBB function and neurovascular-unit biology add further depth to this discussion. BBB function and neurovascular-unit biology are relevant to Alzheimer’s disease pathophysiology and biomarker development.18 This means that vascular biology may influence not only disease mechanisms but also how the field monitors disease, evaluates intervention effects, and identifies patient subgroups. BBB imaging and other measures of neurovascular function may help clarify how vascular and barrier changes contribute to Alzheimer’s disease and related dementias.¹⁸

The therapeutic implications are broad. Vascular and BBB biology may affect how drugs reach the brain, how pathology evolves, how inflammation is regulated, and how cognitive decline emerges in the presence of mixed disease processes. These mechanisms also complicate the interpretation of clinical trials. If a therapy targets amyloid or tau but a patient’s cognitive impairment is also driven by vascular pathology, the measured clinical response may differ from that in a patient with less mixed pathology.

For drug developers, it is essential to design Alzheimer’s programs around real patient biology rather than idealized disease categories. Biomarker strategies that capture only one pathological axis may miss important contributors to disease progression. As the field expands beyond amyloid, vascular biology and BBB function may become increasingly important for trial enrollment, subgroup analysis, safety monitoring, and interpretation of clinical outcomes.

The vascular frame also broadens the meaning of intervention. Alzheimer’s disease treatment may not ultimately consist only of agents that remove or lower hallmark pathologies. It may also include therapies that preserve vascular function, support the neurovascular unit, improve barrier integrity, or reduce the impact of mixed pathologies. Specific interventions will need their own evidentiary basis, but the literature supports vascular and BBB biology as part of the therapeutic-development conversation.

The expansion of Alzheimer’s therapeutic targets naturally leads to the question of combination therapy. Alzheimer’s disease is complex and multifaceted, and combination therapy has become a serious development concept because a single intervention may not address all relevant disease mechanisms. Combination approaches may address amyloid, tau, inflammation, vascular injury, synaptic plasticity, and co-pathologies.⁴

The anti-amyloid era makes this question more practical. Once amyloid-directed antibodies establish a treatment foundation, developers can begin asking which mechanisms should be targeted next, whether combinations should be simultaneous or sequential, and which patients are most likely to benefit. Combination therapy may also help address the biological heterogeneity that makes Alzheimer’s disease so difficult to treat. Patients may differ in amyloid burden, tau pathology, inflammatory state, synaptic damage, mitochondrial impairment, vascular injury, and mixed pathology. A single-target therapy may therefore have different effects depending on the broader disease context.

Clinical-development activity already reflects interest in this direction. As of January 2024, 21 combination trials represented 13% of the Alzheimer’s drug-development pipeline.¹⁹ The field is emphasizing combination therapies after anti-amyloid approvals, with anti-amyloid plus anti-tau combinations and anti-inflammatory / immune combinations highlighted as promising areas.¹⁹ These claims should be used carefully because they are supported at the abstract level, but they are useful for showing that combination therapy is not merely speculative.

Combination development will require more than adding agents together. Developers will need to define the biological rationale for each combination, the appropriate disease stage, and the sequence or timing of intervention. An amyloid-lowering therapy combined with a tau-directed therapy may raise different questions than an amyloid-lowering therapy paired with an immune modulator. A synaptic or mitochondrial approach may need different endpoints than a therapy designed to reduce a protein biomarker. Vascular and BBB-focused interventions may require still another set of measures.

Safety and tolerability will also become increasingly important as combinations move forward. Alzheimer’s disease affects an older population, and many patients may have coexisting medical conditions or mixed pathologies. Combining therapies could increase the complexity of dosing, monitoring, safety management, and interpretation of adverse events. The rationale for combination therapy is strong, but it will need to be matched by disciplined clinical design.

Biomarkers will be central to that discipline. Combination trials may need to show that each component engages its intended target, that the combination produces a broader biological effect than either component alone, and that those effects connect to clinical benefit. This is especially important in a field where changes in pathology, cognition, and function may occur on different timelines. A therapy may show target engagement before clinical benefit is detectable, or it may require use in an earlier disease stage to produce a meaningful effect.

The future of Alzheimer’s development may therefore depend on building combination-ready programs even when therapies are initially tested as monotherapies. Developers may need to understand how their mechanism fits into a broader treatment ecosystem, which biomarkers can support rational pairing, and whether their therapy is best positioned before, during, or after amyloid-directed treatment. As more target classes mature, the most successful programs may be those designed not only around one mechanism but around how that mechanism interacts with the wider disease network.

1. FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval. U.S. Food and Drug Administration. 6 Jul. 2023.

2. FDA Approves Treatment for Adults with Alzheimer’s Disease. U.S. Food and Drug Administration. 2 Jul. 2024.

3. “2026 Alzheimer’s Disease Facts and Figures.” Alzheimer’s & Dementia. 22: e71345 (2026). 5

4. Cummings, Jeffrey L, et al. “Alzheimer’s Disease: Combination Therapies and Clinical Trials for Combination Therapy Development.” CNS Drugs. 38: 613–624 (2024).

5. Congdon, Erin E, et al. “Tau-Targeting Therapies for Alzheimer Disease: Current Status and Future Directions.” Nature Reviews Neurology. 19: 715–736 (2023).

6. Mummery, Catherine J, et al. “Tau-Targeting Antisense Oligonucleotide MAPTRx in Mild Alzheimer’s Disease: A Phase 1b, Randomized, Placebo-Controlled Trial.” Nature Medicine. 29: 1437–1447 (2023).

7. AmeliMojarad, Melika, et al. “The Neuroinflammatory Role of Microglia in Alzheimer’s Disease and Their Associated Therapeutic Targets.” CNS Neuroscience & Therapeutics. 30: e14856 (2024).

8. Duggan, Michael R, et al. “Immune Modulation to Treat Alzheimer’s Disease.” Molecular Neurodegeneration. 20: 39 (2025).

9. Long, Hua, et al. “Preclinical and First-in-Human Evaluation of AL002, a Novel TREM2 Agonistic Antibody for Alzheimer’s Disease.” Alzheimer’s Research & Therapy. 16: 235 (2024).

10. Melchiorri, Daniela, et al. “Alzheimer’s Disease and Neuroinflammation: Will New Drugs in Clinical Trials Pave the Way to a Multi-Target Therapy?” Frontiers in Pharmacology. 14: 1196413 (2023).

11. Meftah, Soraya, and Jian Gan. “Alzheimer’s Disease as a Synaptopathy: Evidence for Dysfunction of Synapses During Disease Progression.” Frontiers in Synaptic Neuroscience. 15: 1129036 (2023).

12. Chen, Yan, Amy KY Fu, and Nancy Y Ip. “Synaptic Dysfunction in Alzheimer’s Disease: Mechanisms and Therapeutic Strategies.” Pharmacology & Therapeutics. 195: 186–198 (2019).

13. Wang, Wenzhang, et al. “Mitochondria Dysfunction in the Pathogenesis of Alzheimer’s Disease: Recent Advances.” Molecular Neurodegeneration. 15: 30 (2020).

14. Percy, Katherine CMG, et al. “Mitochondrial Dysfunction in Alzheimer’s Disease: Guiding the Path to Targeted Therapies.” Neurotherapeutics. 22: e00525 (2025).

15. Mary, Arnaud, et al. “Mitophagy in Alzheimer’s Disease: Molecular Defects and Therapeutic Approaches.” Molecular Psychiatry. 28: 202–216 (2023).

16. Snyder, Heather M, et al. “Vascular Contributions to Cognitive Impairment and Dementia Including Alzheimer’s Disease.” Alzheimer’s & Dementia. 11: 710–717 (2015).

17. Kapasi, Arvanitakis, and Julie A Schneider. “Vascular Contributions to Cognitive Impairment, Clinical Alzheimer’s Disease, and Dementia in Older Persons.” Biochimica et Biophysica Acta — Molecular Basis of Disease. 1862: 878–886 (2016).

18. Uchida, Yuto, et al. “Contributions of Blood–Brain Barrier Imaging to Neurovascular Unit Pathophysiology of Alzheimer’s Disease and Related Dementias.” Frontiers in Aging Neuroscience. 15: 1111448 (2023).

19. Angioni, D, et al. “Challenges and Opportunities for Novel Combination Therapies in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force.” The Journal of Prevention of Alzheimer’s Disease. 12: 100163 (2025).